Posted by Michael Wonder on 23 Oct 2017
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
23 October 2017 - NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar for treating certain patients with thyroid cancer.
The decision relates to advanced differentiated thyroid cancer that has spread to other parts of the body and cannot be operated on, in adults whose disease does not respond to radioactive iodine.
The committee heard that thyroid cancer is rare, and that the only option for patients unable to receive treatment with Lenvima (lenvatinib) or Nexavar (sorafenib) is best supportive care.
